Alnylam Pharmaceuticals
Prix: 282.85Entreprise et modèle économique
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the development of therapies based on RNA interference (RNAi) technology. Its core products include treatments for genetic diseases and conditions related to liver and cardiovascular health. Major business segments encompass rare diseases and cardiovascular diseases, with primary revenue sources stemming from product sales and collaborations with other pharmaceutical companies.
Profil d’investissement
The investment profile of Alnylam Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential market expansion. However, the high risk associated with its volatility and market performance may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential future gains.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 4.36 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 6.4% ↑
- Surprise BPA
- 73.2% meilleur que prévu
- Volatilité 20 j
- 2.1% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:58 | Conserver | Vendre | Weak momentum and high risk overshadow potential growth. |
| 2026-05-24 02:31 | Vendre | Conserver | Strong EPS surprise, but negative momentum raises concerns. |
| 2026-05-16 02:47 | Conserver | Vendre | Weak momentum and high risk overshadow positive fundamentals. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-01 15:46 | Morgan Stanley | Objectif relevé | 360 → 370 | 301.4499 |
| 2026-05-01 13:04 | Bernstein | Objectif abaissé | 448 → 447 | 302.85001 |
| 2026-02-17 12:18 | Canaccord Genuity | Objectif relevé | 415 → 429 | 314.4 |
Rien pour le moment